HemoGenix LLC
This article was originally published in Start Up
Executive Summary
Pharmaceutical companies are increasingly looking to in vitro assays that can be done very early in the discovery and lead optimization process to help them determine a compound's safety before investing further. Ivan Rich, the founder of HemoGenix, believes that hematopoietic stem cells, which are responsible for producing all cells of the blood forming system, are an under-used source for the early prediction of drug toxicity.